Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study
- Resource Type
- Article
- Source
- The Lancet; March 2019, Vol. 393 Issue: 10174 p889-898, 10p
- Subject
- Language
- ISSN
- 01406736; 1474547X